

# Hans Lilja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/417171/publications.pdf>

Version: 2024-02-01

362  
papers

31,751  
citations

4658

85  
h-index

4991

167  
g-index

374  
all docs

374  
docs citations

374  
times ranked

20631  
citing authors

#	ARTICLE	IF	CITATIONS
1	How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?. <i>European Urology Oncology</i> , 2022, 5, 135-137.	5.4	11
2	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199.	2.5	13
3	Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. <i>British Journal of Cancer</i> , 2022, 126, 1004-1009.	6.4	2
4	Prostate cancer polygenic risk score and prediction of lethal prostate cancer. <i>Npj Precision Oncology</i> , 2022, 6, 25.	5.4	20
5	Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. <i>Journal of Urology</i> , 2022, 208, 292-300.	0.4	31
6	PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172.		2
7	Prospective validation of microseminoprotein-2 added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. <i>BJU International</i> , 2021, 128, 218-224.	2.5	3
8	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. <i>Clinical Cancer Research</i> , 2021, 27, 2050-2060.	7.0	13
9	High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 631021.	2.8	17
10	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2000025.	1.6	3
11	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. <i>Urology</i> , 2021, , .	1.0	1
12	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	10.7	48
13	Modern prostate cancer diagnostics reduce overdiagnosis – will they open up for population-based screening?. <i>Scandinavian Journal of Urology</i> , 2021, 55, 491-492.	1.0	0
14	Two-Step Acoustophoresis Separation of Live Tumor Cells from Whole Blood. <i>Analytical Chemistry</i> , 2021, 93, 17076-17085.	6.5	23
15	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. <i>Prostate</i> , 2020, 80, 51-56.	2.3	5
16	Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels. <i>Prostate</i> , 2020, 80, 1405-1412.	2.3	3
17	The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1381-1388.	2.5	22
18	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. <i>British Journal of Cancer</i> , 2020, 123, 604-609.	6.4	9

#	ARTICLE	IF	CITATIONS
19	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted $\hat{1}\pm$ -particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181.	7.1	16
20	Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Human Molecular Genetics, 2020, 29, 1581-1591.	2.9	8
21	Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years. JAMA Network Open, 2020, 3, e1919284.	5.9	33
22	Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. Journal of Urology, 2020, 204, 71-78.	0.4	8
23	Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Journal of Urology, 2020, 204, 281-288.	0.4	19
24	Abstract PR01: The four-kallikrein panel discriminates prostate cancer and aggressive disease in a multiethnic population. , 2020, , .		0
25	Reply by Authors. Journal of Urology, 2020, 204, 287-288.	0.4	0
26	Reply by Authors. Journal of Urology, 2020, 204, 77-78.	0.4	0
27	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
28	A urinary extracellular vesicle microRNA biomarker discovery pipeline; from automated extracellular vesicle enrichment by acoustic trapping to microRNA sequencing. PLoS ONE, 2019, 14, e0217507.	2.5	17
29	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate, 2019, 79, 1079-1089.	2.3	28
30	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51.	1.9	359
31	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	1.9	43
32	Clinical Chemistry's Special Issue on Men's Health. Clinical Chemistry, 2019, 65, 1-3.	3.2	6
33	Perspective on Prostate Cancer Screening. Clinical Chemistry, 2019, 65, 24-27.	3.2	7
34	Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-967. European Urology, 2019, 75, e56.	1.9	0
35	Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. Clinical Chemistry, 2019, 65, e1-e9.	3.2	17
36	A Four-kallikrein Panel and $\hat{1}^2$ -Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2019, 5, 561-567.	3.1	8

#	ARTICLE	IF	CITATIONS
37	Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. <i>Clinical Cancer Research</i> , 2018, 24, 2408-2416.	7.0	19
38	Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. <i>European Urology</i> , 2018, 73, 941-948.	1.9	30
39	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1470-1474.	0.4	11
40	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018, 9, 1629.	12.8	37
41	Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. <i>Scandinavian Journal of Urology</i> , 2018, 52, 27-37.	1.0	53
42	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	6.4	12
43	Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. <i>European Urology</i> , 2018, 73, 961-967.	1.9	14
44	Reducing WBC background in cancer cell separation products by negative acoustic contrast particle immuno-acoustophoresis. <i>Analytica Chimica Acta</i> , 2018, 1000, 256-264.	5.4	42
45	Prostate cancer risk assessment in men with an initial P.S.A. below 3â€‰ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. <i>Scandinavian Journal of Urology</i> , 2018, 52, 256-262.	1.0	9
46	Acoustic Enrichment of Extracellular Vesicles from Biological Fluids. <i>Analytical Chemistry</i> , 2018, 90, 8011-8019.	6.5	85
47	Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. <i>European Urology</i> , 2018, 74, 710-719.	1.9	47
48	Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139â€“46. <i>European Urology</i> , 2018, 74, e35-e36.	1.9	2
49	Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. <i>Oncotarget</i> , 2018, 9, 5778-5785.	1.8	1
50	A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5073-5073.	1.6	0
51	Screening for Prostate Cancer Starting at Age 50â€“54 Years. A Population-based Cohort Study. <i>European Urology</i> , 2017, 71, 46-52.	1.9	42
52	Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. <i>Nature Communications</i> , 2017, 8, 14248.	12.8	58
53	Clinical-Scale Cell-Surface-Marker Independent Acoustic Microfluidic Enrichment of Tumor Cells from Blood. <i>Analytical Chemistry</i> , 2017, 89, 11954-11961.	6.5	50
54	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. <i>Journal of Urology</i> , 2017, 197, 1041-1047.	0.4	23

#	ARTICLE	IF	CITATIONS
55	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017, 197, 607-613.	0.4	18
56	Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC). <i>Journal of Clinical Oncology</i> , 2017, 35, 1297-1303.	1.6	18
57	Abstract B28: Baseline prostate-specific antigen (PSA) levels in midlife predict aggressive prostate cancer in African-American men. , 2017, , .		0
58	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0150241.	2.5	28
59	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016, 8, 367ra167.	12.4	23
60	Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 311-322.	2.5	0
61	Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. <i>Urology</i> , 2016, 95, 224.	1.0	0
62	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016, 122, 3386-3393.	4.1	23
63	Porous silicon microarray for simultaneous fluorometric immunoassay of the biomarkers prostate-specific antigen and human glandular kallikrein 2. <i>Mikrochimica Acta</i> , 2016, 183, 3321-3327.	5.0	9
64	Beyond prostate-specific antigen. <i>Current Opinion in Urology</i> , 2016, 26, 459-465.	1.8	38
65	Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 993-994.	1.9	4
66	The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. <i>Urology</i> , 2016, 91, 12-18.	1.0	54
67	A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. <i>European Urology</i> , 2016, 69, 505-511.	1.9	77
68	Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. <i>Oncotarget</i> , 2016, 7, 1107-1119.	1.8	5
69	Abstract 3389: Androgen deprivation therapy potentiates the efficacy of vascular targeted photodynamic therapy of prostate cancer xenografts. , 2016, , .		0
70	Serum markers in prostate cancer detection. <i>Current Opinion in Urology</i> , 2015, 25, 59-64.	1.8	14
71	miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen. <i>European Urology</i> , 2015, 68, 581-588.	1.9	35
72	Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial. <i>European Urology</i> , 2015, 68, 354-360.	1.9	110

#	ARTICLE	IF	CITATIONS
73	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015, 68, 139-146.	1.9	156
74	miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. <i>Carcinogenesis</i> , 2015, 36, 858-866.	2.8	56
75	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015, 68, 1033-1044.	1.9	166
76	Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. <i>Nuclear Medicine and Biology</i> , 2015, 42, 375-380.	0.6	9
77	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. <i>European Urology</i> , 2015, 68, 1076-1082.	1.9	12
78	A single inlet two-stage acoustophoresis chip enabling tumor cell enrichment from white blood cells. <i>Lab on A Chip</i> , 2015, 15, 2102-2109.	6.0	92
79	Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era. <i>European Urology Focus</i> , 2015, 1, 149-151.	3.1	0
80	A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer. <i>Sensors</i> , 2015, 15, 11972-11987.	3.8	10
81	Acoustofluidic, Label-Free Separation and Simultaneous Concentration of Rare Tumor Cells from White Blood Cells. <i>Analytical Chemistry</i> , 2015, 87, 9322-9328.	6.5	131
82	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	146
83	Concurrent Isolation of Lymphocytes and Granulocytes Using Prefocused Free Flow Acoustophoresis. <i>Analytical Chemistry</i> , 2015, 87, 5596-5604.	6.5	48
84	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Caseâ€“Control Study. <i>European Urology</i> , 2015, 68, 207-213.	1.9	120
85	Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a <sup>111</sup> In-radiolabelled monoclonal antibody, 11B6. <i>EJNMMI Research</i> , 2014, 4, 51.	2.5	20
86	Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3082-3096.	3.8	27
87	Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. <i>BMJ, The</i> , 2014, 348, g2296-g2296.	6.0	79
88	Genetic Variation in KLK2 and KLK3 Is Associated with Concentrations of hK2 and PSA in Serum and Seminal Plasma in Young Men. <i>Clinical Chemistry</i> , 2014, 60, 490-499.	3.2	21
89	Identification of plasma protein profiles associated with risk groups of prostate cancer patients. <i>Proteomics - Clinical Applications</i> , 2014, 8, 951-962.	1.6	10
90	Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju007-dju007.	6.3	36

#	ARTICLE	IF	CITATIONS
91	MALDI-target integrated platform for affinity-captured protein digestion. <i>Analytica Chimica Acta</i> , 2014, 807, 1-8.	5.4	9
92	Emerging PSA-Based Tests to Improve Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 267-276.	1.8	23
93	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2014, 32, 185-191.	2.2	28
94	It Ain't™t What You Do, It's the Way You Do It: Five Golden Rules for Transforming Prostate-Specific Antigen Screening. <i>European Urology</i> , 2014, 66, 188-190.	1.9	21
95	Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. <i>BMC Medicine</i> , 2014, 12, 26.	5.5	88
96	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	1.9	195
97	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014, 384, 2027-2035.	13.7	1,261
98	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014, 15, e484-e492.	10.7	372
99	Analytic and Clinical Validation of a Prostate Cancer-Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. <i>European Urology</i> , 2014, 65, 1191-1197.	1.9	66
100	Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens. <i>Urology</i> , 2014, 83, 511.e1-511.e7.	1.0	15
101	Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium. <i>Journal of Proteome Research</i> , 2013, 12, 135-150.	3.7	16
102	miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 1668-1676.	6.4	110
103	Genome-wide Association Study Identifies Loci at ATF7IP and KLK2 Associated with Percentage of Circulating Free PSA. <i>Neoplasia</i> , 2013, 15, 95-IN30.	5.3	11
104	Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody. <i>Analytica Chimica Acta</i> , 2013, 796, 108-114.	5.4	22
105	Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. <i>European Urology</i> , 2013, 64, 693-699.	1.9	78
106	Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. <i>European Journal of Cancer</i> , 2013, 49, 3041-3048.	2.8	12
107	Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial. <i>European Urology</i> , 2013, 64, 873-875.	1.9	43
108	Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. <i>Clinical Biochemistry</i> , 2013, 46, 670-674.	1.9	11

#	ARTICLE	IF	CITATIONS
109	Integrated acoustic immunoaffinity-capture (IAI) platform for detection of PSA from whole blood samples. <i>Lab on A Chip</i> , 2013, 13, 1790.	6.0	26
110	Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. <i>BMJ, The</i> , 2013, 346, f2023-f2023.	6.0	221
111	Suitability of quality control materials for prostate-specific antigen (PSA) measurement: inter-method variability of common tumor marker control materials. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 873-880.	2.3	5
112	Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 237-243.	6.3	42
113	Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. <i>International Journal of Cancer</i> , 2013, 133, 1452-1458.	5.1	64
114	Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 2761-2773.	3.8	40
115	Can one blood draw replace transrectal ultrasonographyâ€™estimated prostate volume to predict prostate cancer risk?. <i>BJU International</i> , 2013, 112, 602-609.	2.5	10
116	Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. <i>Thrombosis and Haemostasis</i> , 2013, 110, 484-492.	3.4	43
117	Microchannel Acoustophoresis does not Impact Survival or Function of Microglia, Leukocytes or Tumor Cells. <i>PLoS ONE</i> , 2013, 8, e64233.	2.5	101
118	Copy Number Variants in the Kallikrein Gene Cluster. <i>PLoS ONE</i> , 2013, 8, e69097.	2.5	2
119	Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen. <i>Cancer Discovery</i> , 2012, 2, 320-327.	9.4	68
120	Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review. <i>Journal of Clinical Oncology</i> , 2012, 30, 2581-2584.	1.6	114
121	Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 682-687.	0.7	6
122	Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1993-1998.	2.3	8
123	Screening for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 539.	3.9	1
124	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012, 30, 181-187.	2.2	66
125	Porous silicon antibody microarrays for quantitative analysis: Measurement of free and total PSA in clinical plasma samples. <i>Clinica Chimica Acta</i> , 2012, 414, 76-84.	1.1	24
126	Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. <i>Clinical Biochemistry</i> , 2012, 45, 331-338.	1.9	17



#	ARTICLE	IF	CITATIONS
127	NADiA ProVue Prostate-specific Antigen Slope Is an Independent Prognostic Marker for Identifying Men at Reduced Risk of Clinical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Urology</i> , 2012, 80, 1319-1327.	1.0	14
128	We Need a Better Marker for Prostate Cancer. How About Renaming PSA?. <i>Urology</i> , 2012, 79, 254-255.	1.0	10
129	Microfluidic, Label-Free Enrichment of Prostate Cancer Cells in Blood Based on Acoustophoresis. <i>Analytical Chemistry</i> , 2012, 84, 7954-7962.	6.5	287
130	Targeting Free Prostate-Specific Antigen for <i>In Vivo</i> Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 243-251.	1.0	12
131	Prostate-Cancer Mortality at 11 Years of Follow-up. <i>New England Journal of Medicine</i> , 2012, 366, 981-990.	27.0	1,105
132	Time for another rethink on prostate cancer screening. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 7-8.	27.6	1
133	Screening for Prostate Cancer: Early Detection or Overdetection?. <i>Annual Review of Medicine</i> , 2012, 63, 161-170.	12.2	43
134	Predicting prostate cancer many years before diagnosis: how and why?. <i>World Journal of Urology</i> , 2012, 30, 131-135.	2.2	17
135	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012, 30, 149-155.	2.2	101
136	Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men. <i>European Urology</i> , 2012, 61, 471-477.	1.9	46
137	PSA is Dead, Long Live PSA. <i>European Urology</i> , 2012, 61, 467-468.	1.9	8
138	A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index. <i>European Urology</i> , 2012, 62, 78-84.	1.9	158
139	Tumor markers in prostate cancer I: Blood-based markers. <i>Acta Oncologica</i> , 2011, 50, 61-75.	1.8	144
140	Editorial Comment. <i>Urology</i> , 2011, 78, 606.	1.0	0
141	Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. <i>BJU International</i> , 2011, 107, 28-39.	2.5	83
142	Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. <i>BJU International</i> , 2011, 107, 1769-1774.	2.5	10
143	Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys145 or Lys146 from fPSA without internal cleavages at Lys145 or Lys146. <i>Journal of Immunological Methods</i> , 2011, 369, 74-80.	1.4	10
144	Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples. <i>Journal of Proteomics</i> , 2011, 75, 202-210.	2.4	2

#	ARTICLE	IF	CITATIONS
145	TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate. <i>European Urology</i> , 2011, 60, 897-904.	1.9	176
146	Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products. <i>BMC Biochemistry</i> , 2011, 12, 55.	4.4	13
147	Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. <i>Cancer</i> , 2011, 117, 1210-1219.	4.1	121
148	Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. <i>International Journal of Cancer</i> , 2011, 128, 2373-2381.	5.1	18
149	A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 255-261.	2.5	84
150	An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2011, 103, 462-469.	6.3	113
151	DETECTION OF PROSTATE CANCER: PSA. , 2011, , 283-334.		3
152	Prostate Cancer Early Detection. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 240-262.	4.9	132
153	A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. <i>BMC Cancer</i> , 2010, 10, 635.	2.6	70
154	Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen. <i>Cancer</i> , 2010, 116, 2612-2620.	4.1	61
155	miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. <i>International Journal of Cancer</i> , 2010, 127, 2768-2776.	5.1	145
156	Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. <i>Journal of Proteomics</i> , 2010, 73, 1137-1147.	2.4	20
157	A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. <i>British Journal of Cancer</i> , 2010, 103, 708-714.	6.4	99
158	The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microsemipoprotein-Beta Expression in Tissue and Urine. <i>PLoS ONE</i> , 2010, 5, e13363.	2.5	73
159	Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 611-619.	1.5	60
160	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication. <i>Journal of Clinical Oncology</i> , 2010, 28, 2493-2498.	1.6	204
161	Detection of Androgen Receptor Mutations in Circulating Tumor Cells: Highlights of the Long Road to Clinical Qualification. <i>Clinical Chemistry</i> , 2010, 56, 1375-1377.	3.2	4
162	Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated?. <i>Journal of Clinical Oncology</i> , 2010, 28, 1112-1116.	1.6	19

#	ARTICLE	IF	CITATIONS
163	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010, 16, 4374-4381.	7.0	86
164	A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. <i>Clinical Cancer Research</i> , 2010, 16, 3232-3239.	7.0	106
165	A Common Prostate Cancer Risk Variant 5â€² of <i>Microseminoprotein-Î² (MSMB)</i> Is a Strong Predictor of Circulating Î²-Microseminoprotein (MSP) Levels in Multiple Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2639-2646.	2.5	17
166	Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1201-1207.	2.5	30
167	Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 369-375.	3.9	27
168	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4521-c4521.	2.3	195
169	Polymorphisms at the Microseminoprotein-Î² Locus Associated with Physiologic Variation in Î²-Microseminoprotein and Prostate-Specific Antigen Levels. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2035-2042.	2.5	27
170	Susceptibility Loci Associated with Prostate Cancer Progression and Mortality. <i>Clinical Cancer Research</i> , 2010, 16, 2819-2832.	7.0	74
171	1986 AN EMPIRICAL EVALUATION OF THE NATIONAL CANCER CENTER NETWORK GUIDELINES ON PROSTATE SPECIFIC ANTIGEN VELOCITY IN PROSTATE CANCER DETECTION. <i>Journal of Urology</i> , 2010, 183, .	0.4	2
172	On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. <i>European Journal of Cancer</i> , 2010, 46, 3109-3119.	2.8	20
173	Mortality results from the GÃ¶teborg randomised population-based prostate-cancer screening trial. <i>Lancet Oncology</i> , The, 2010, 11, 725-732.	10.7	843
174	Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy. <i>Journal of Urology</i> , 2010, 184, 907-912.	0.4	24
175	Pretreatment Prostate-Specific Antigen (PSA) Velocity and Doubling Time Are Associated With Outcome but Neither Improves Prediction of Outcome Beyond Pretreatment PSA Alone in Patients Treated With Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3591-3597.	1.6	79
176	Cutpoints in Clinical Chemistry: Time for Fundamental Reassessment. <i>Clinical Chemistry</i> , 2009, 55, 15-17.	3.2	27
177	Estimating the benefits of PSA screening. <i>Nature Reviews Urology</i> , 2009, 6, 301-303.	3.8	17
178	Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2000-2005.	2.5	10
179	Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 398-403.	1.6	225
180	Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival. <i>Clinical Chemistry</i> , 2009, 55, 765-773.	3.2	122

#	ARTICLE	IF	CITATIONS
181	Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). <i>European Urology</i> , 2009, 56, 584-591.	1.9	180
182	Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort. <i>European Urology</i> , 2009, 56, 753-760.	1.9	65
183	Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. <i>International Journal of Cancer</i> , 2009, 124, 659-663.	5.1	20
184	Risk of dying from prostate cancer in men randomized to screening. <i>Cancer</i> , 2009, 115, 5672-5679.	4.1	17
185	Molecular insights into substrate specificity of prostate specific antigen through structural modeling. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 77, 984-993.	2.6	14
186	Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. <i>Prostate</i> , 2009, 69, 419-427.	2.3	36
187	THE CONTINUING ROLE OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR LOCALIZED PROSTATE CANCER: "DO NOT THROW THE BABY OUT WITH THE BATH WATER". <i>BJU International</i> , 2009, 104, 1553-1554.	2.5	4
188	Fluorescence <i>in situ</i> Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2091-2097.	7.0	185
189	Acoustic Whole Blood Plasmapheresis Chip for Prostate Specific Antigen Microarray Diagnostics. <i>Analytical Chemistry</i> , 2009, 81, 6030-6037.	6.5	189
190	Prostate kallikrein markers in diagnosis, risk stratification and prognosis. <i>Nature Reviews Urology</i> , 2009, 6, 384-391.	3.8	40
191	NF- $\kappa$ B Regulates Androgen Receptor Expression and Prostate Cancer Growth. <i>American Journal of Pathology</i> , 2009, 175, 489-499.	3.8	163
192	Screening and Prostate-Cancer Mortality in a Randomized European Study. <i>New England Journal of Medicine</i> , 2009, 360, 1320-1328.	27.0	3,540
193	Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. <i>Current Opinion in Urology</i> , 2009, 19, 221-226.	1.8	31
194	Systematic review of statistical methods used in molecular marker studies in cancer. <i>Cancer</i> , 2008, 112, 1862-1868.	4.1	35
195	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. <i>Clinical Chemistry</i> , 2008, 54, e11-e79.	3.2	539
196	Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. <i>Nature Reviews Cancer</i> , 2008, 8, 268-278.	28.4	713
197	A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in GÅrteborg, Sweden. <i>BMC Medicine</i> , 2008, 6, 19.	5.5	212
198	Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. <i>BMC Medicine</i> , 2008, 6, 6.	5.5	95

#	ARTICLE	IF	CITATIONS
199	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	16.8	303
200	Serum Markers for Prostate Cancer: A Rational Approach to the Literature. <i>European Urology</i> , 2008, 54, 31-40.	1.9	48
201	Beta $\alpha$ -Microseminoprotein in Serum Correlates With the Levels in Seminal Plasma of Young, Healthy Males. <i>Journal of Andrology</i> , 2008, 29, 330-337.	2.0	20
202	ENSAM: Europium Nanoparticles for Signal Enhancement of Antibody Microarrays on Nanoporous Silicon. <i>Journal of Proteome Research</i> , 2008, 7, 1308-1314.	3.7	36
203	Increase in percent free prostate-specific antigen in men with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 1238-1241.	0.7	25
204	Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population. <i>Journal of Clinical Oncology</i> , 2008, 26, 835-841.	1.6	95
205	Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer. <i>Clinical Chemistry</i> , 2008, 54, 1248-1249.	3.2	7
206	Screening for prostate cancer: an update. <i>Canadian Journal of Urology</i> , 2008, 15, 4363-74.	0.0	34
207	Five genetic variants associated with prostate cancer. <i>New England Journal of Medicine</i> , 2008, 358, 2740; author reply 2741.	27.0	3
208	Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer. <i>Clinical Chemistry</i> , 2007, 53, 233-240.	3.2	57
209	Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 347-348.	1.6	10
210	Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 7053-7058.	7.0	608
211	Can PSA velocity predict risk of death in men with prostate cancer?. <i>Nature Reviews Urology</i> , 2007, 4, 410-411.	1.4	3
212	Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1484-1489.	6.3	198
213	Association of Cysteine-Rich Secretory Protein 3 and $\beta$ -Microseminoprotein with Outcome after Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 4130-4138.	7.0	76
214	Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2023-2029.	7.0	329
215	Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years. <i>Journal of Clinical Oncology</i> , 2007, 25, 431-436.	1.6	187
216	A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue. <i>Biological Chemistry</i> , 2007, 388, 289-95.	2.5	17

#	ARTICLE	IF	CITATIONS
217	PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. <i>International Journal of Cancer</i> , 2007, 120, 170-174.	5.1	133
218	Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. <i>International Journal of Cancer</i> , 2007, 120, 1499-1504.	5.1	41
219	The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically based screening strategy. <i>International Journal of Cancer</i> , 2007, 121, 2212-2217.	5.1	42
220	Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood. <i>Clinical Biochemistry</i> , 2007, 40, 111-118.	1.9	11
221	Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial. <i>European Urology</i> , 2007, 51, 659-664.	1.9	105
222	Circulating biomarkers for prostate cancer. <i>World Journal of Urology</i> , 2007, 25, 111-119.	2.2	33
223	Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein-2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab') <sub>2</sub> Fragments. <i>Analytical Chemistry</i> , 2006, 78, 7809-7815.	6.5	61
224	Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. <i>Prostate</i> , 2006, 66, 591-603.	2.3	44
225	Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. <i>Prostate</i> , 2006, 66, 358-368.	2.3	49
226	High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry. <i>Electrophoresis</i> , 2006, 27, 1093-1103.	2.4	42
227	Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. <i>International Journal of Cancer</i> , 2006, 118, 1234-1240.	5.1	48
228	Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in Serum. <i>Clinical Chemistry</i> , 2006, 52, 838-844.	3.2	49
229	Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition. <i>Journal of Clinical Oncology</i> , 2006, 24, 3973-3978.	1.6	456
230	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. <i>Biological Chemistry</i> , 2006, 387, 637-41.	2.5	123
231	Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at 20 °C. <i>Clinical Chemistry</i> , 2006, 52, 235-239.	3.2	62
232	Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level. <i>Archives of Internal Medicine</i> , 2005, 165, 1857.	3.8	76
233	Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. <i>International Journal of Cancer</i> , 2005, 113, 290-297.	5.1	54
234	Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. <i>Current Prostate Reports</i> , 2005, 3, 11-20.	0.1	0

#	ARTICLE	IF	CITATIONS
235	Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. <i>Prostate</i> , 2005, 63, 13-18.	2.3	35
236	Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. <i>Prostate</i> , 2005, 65, 66-72.	2.3	31
237	Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. <i>Prostate</i> , 2005, 65, 216-221.	2.3	25
238	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 64-81.	1.4	63
239	Translational Crossroads for Biomarkers. <i>Clinical Cancer Research</i> , 2005, 11, 6103-6108.	7.0	73
240	Differential exoprotease activities confer tumor-specific serum peptidome patterns. <i>Journal of Clinical Investigation</i> , 2005, 116, 271-284.	8.2	683
241	COMPARISON OF PREDICTIVE ACCURACY FOR PATHOLOGICALLY ORGAN CONFINED CLINICAL STAGE T1c PROSTATE CANCER USING HUMAN GLANDULAR KALLIKREIN 2 AND PROSTATE SPECIFIC ANTIGEN COMBINED WITH CLINICAL STAGE AND GLEASON GRADE. <i>Journal of Urology</i> , 2005, 173, 752-756.	0.4	25
242	TESTOSTERONE AS A PREDICTOR OF PATHOLOGICAL STAGE IN CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 173, 1935-1937.	0.4	131
243	The evolution of a genetic locus encoding small serine proteinase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 383-389.	2.1	85
244	Î <sup>2</sup> -Microseminoprotein binds CRISP-3 in human seminal plasma. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 555-561.	2.1	59
245	Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2. <i>Clinical Chemistry</i> , 2004, 50, 1607-1617.	3.2	47
246	Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio. <i>European Urology</i> , 2004, 45, 160-165.	1.9	16
247	Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. <i>Current Urology Reports</i> , 2004, 5, 231-240.	2.2	12
248	Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence. <i>Prostate</i> , 2004, 59, 227-233.	2.3	22
249	Integrated selective enrichment target - a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases. <i>Electrophoresis</i> , 2004, 25, 3769-3777.	2.4	42
250	Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. <i>Cancer</i> , 2004, 100, 1397-1405.	4.1	111
251	Lead time associated with screening for prostate cancer. <i>International Journal of Cancer</i> , 2004, 108, 122-129.	5.1	76
252	THE RISK OF FINDING FOCAL CANCER (LESS THAN 3 MM) REMAINS HIGH ON RE-BIOPSY OF PATIENTS WITH PERSISTENTLY INCREASED PROSTATE SPECIFIC ANTIGEN BUT THE CLINICAL SIGNIFICANCE IS QUESTIONABLE. <i>Journal of Urology</i> , 2004, 171, 1500-1503.	0.4	49

#	ARTICLE	IF	CITATIONS
253	RAPID ELIMINATION BY GLOMERULAR FILTRATION OF FREE PROSTATE SPECIFIC ANTIGEN AND HUMAN KALLIKREIN 2 AFTER RENAL TRANSPLANTATION. <i>Journal of Urology</i> , 2004, 171, 1432-1435.	0.4	28
254	The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin. <i>Gene</i> , 2004, 343, 347-355.	2.2	21
255	Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen. <i>Genomics</i> , 2004, 84, 147-156.	2.9	51
256	Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1439-50.	4.1	28
257	Follow-Up of Men with Elevated Prostate-Specific Antigen and One Set of Benign Biopsies at Prostate Cancer Screening. <i>European Urology</i> , 2003, 43, 327-332.	1.9	36
258	Expression and Immunolocalisation of Neutral Endopeptidase in Prostate Cancer. <i>European Urology</i> , 2003, 44, 415-422.	1.9	13
259	The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. <i>Prostate</i> , 2003, 54, 181-186.	2.3	59
260	Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. <i>Prostate</i> , 2003, 56, 45-53.	2.3	34
261	Quantitative PSA RT-PCR for preoperative staging of prostate cancer. <i>Prostate</i> , 2003, 56, 263-269.	2.3	13
262	Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. <i>Prostate</i> , 2003, 57, 196-204.	2.3	34
263	Prostate Specific Antigen Based Biennial Screening is Sufficient to Detect Almost All Prostate Cancers While Still Curable. <i>Journal of Urology</i> , 2003, 169, 1720-1723.	0.4	45
264	Total and Gleason Grade 4/5 Cancer Volumes are Major Contributors of Human Kallikrein 2, Whereas Free Prostate Specific Antigen is Largely Contributed by Benign Gland Volume in Serum From Patients With Prostate Cancer or Benign Prostatic Biopsies. <i>Journal of Urology</i> , 2003, 170, 2269-2273.	0.4	40
265	Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. <i>Urology</i> , 2003, 62, 278-281.	1.0	28
266	Biology of prostate-specific antigen. <i>Urology</i> , 2003, 62, 27-33.	1.0	104
267	Inhibition of Dendropoiesis by Tumor Derived and Purified Prostate Specific Antigen. <i>Journal of Urology</i> , 2003, 170, 2026-2030.	0.4	47
268	Testing in Serum for Human Glandular Kallikrein 2, and Free and Total Prostate Specific Antigen in Biannual Screening for Prostate Cancer. <i>Journal of Urology</i> , 2003, 170, 1169-1174.	0.4	21
269	Standardization of Two Immunoassays for Human Glandular Kallikrein 2. <i>Clinical Chemistry</i> , 2003, 49, 601-610.	3.2	23
270	Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 990-1000.	6.3	274



#	ARTICLE	IF	CITATIONS
271	Serum Cystatin C Is a More Sensitive and More Accurate Marker of Glomerular Filtration Rate than Enzymatic Measurements of Creatinine in Renal Transplantation. <i>Nephron Physiology</i> , 2003, 94, p19-p27.	1.2	67
272	A frequent allele codes for a truncated variant of semenogelin I, the major protein component of human semen coagulum. <i>Molecular Human Reproduction</i> , 2003, 9, 345-350.	2.8	14
273	Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage T1-T2) in prostate cancer patients. <i>Urology</i> , 2003, 61, 1078-1083.	1.4	10
274	Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 598-603.	0.7	44
275	A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. <i>Biochemical Journal</i> , 2002, 368, 233-242.	3.7	190
276	Anti-Thrombin Is Expressed in the Benign Prostatic Epithelium and in Prostate Cancer and Is Capable of Forming Complexes with Prostate-Specific Antigen and Human Glandular Kallikrein 2. <i>American Journal of Pathology</i> , 2002, 161, 2053-2063.	3.8	24
277	Prediction of tumor heterogeneity in localized prostate cancer. <i>Urologic Clinics of North America</i> , 2002, 29, 213-222.	1.8	8
278	Discrimination of Benign From Malignant Prostatic Disease by Selective Measurements of Single Chain, Intact Free Prostate Specific Antigen. <i>Journal of Urology</i> , 2002, 168, 1917-1922.	0.4	46
279	Simultaneous Quantification of Prostate-specific Antigen and Human Glandular Kallikrein 2 mRNA in Blood Samples from Patients with Prostate Cancer and Benign Disease. <i>Clinical Chemistry</i> , 2002, 48, 1265-1271.	3.2	14
280	Discrimination of Benign From Malignant Prostatic Disease by Selective Measurements of Single Chain, Intact Free Prostate Specific Antigen. <i>Journal of Urology</i> , 2002, , 1917-1922.	0.4	0
281	Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. <i>Clinical Cancer Research</i> , 2002, 8, 156-64.	7.0	107
282	Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. <i>Clinical Chemistry</i> , 2002, 48, 1257-64.	3.2	36
283	Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. <i>Journal of Urology</i> , 2002, 168, 1917-22.	0.4	12
284	Simultaneous Quantification of Human Glandular Kallikrein 2 and Prostate-Specific Antigen mRNAs in Peripheral Blood from Prostate Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2001, 3, 111-122.	2.8	17
285	The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001, 38, 357-399.	6.1	26
286	Tumor Volume Is a Valid Surrogate Endpoint for Defining Clinically Significant Prostate Cancers. <i>European Urology</i> , 2001, 39, 33-34.	1.9	3
287	Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing. <i>Clinical Chemistry</i> , 2001, 47, 703-711.	3.2	10
288	Dual-Label Detection of Amplified Products in Quantitative RT-PCR Assay Using Lanthanide-Labeled Probes. <i>BioTechniques</i> , 2001, 30, 832-845.	1.8	11

#	ARTICLE	IF	CITATIONS
289	Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146. <i>Clinical Chemistry</i> , 2001, 47, 1415-1423.	3.2	82
290	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hk2) in prostate cancer patients treated with GnRH-analogues. <i>Prostate</i> , 2001, 47, 14-20.	2.3	3
291	Activation of latent protease function of pro-hk2, but not pro-PSA, involves autoprocessing. <i>Prostate</i> , 2001, 48, 122-126.	2.3	32
292	Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. <i>Prostate</i> , 2001, 49, 101-109.	2.3	82
293	Enzymatic action of prostate-specific antigen (PSA or hk3): Substrate specificity and regulation by Zn <sup>2+</sup> , a tight-binding inhibitor. <i>Prostate</i> , 2000, 45, 132-139.	2.3	152
294	Time-resolved fluorometry in end-point and real-time PCR quantification of nucleic acids. <i>Luminescence</i> , 2000, 15, 381-388.	2.9	24
295	Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. <i>Luminescence</i> , 2000, 15, 389-397.	2.9	49
296	New Nomenclature for the Human Tissue Kallikrein Gene Family. <i>Clinical Chemistry</i> , 2000, 46, 1855-1858.	3.2	163
297	Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA. <i>Clinical Chemistry</i> , 2000, 46, 1610-1618.	3.2	60
298	Streptavidin-Polyvinylamine Conjugates Labeled with a Europium Chelate: Applications in Immunoassay, Immunohistochemistry, and Microarrays. <i>Clinical Chemistry</i> , 2000, 46, 1450-1455.	3.2	69
299	Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum. <i>Clinical Chemistry</i> , 2000, 46, 198-206.	3.2	58
300	The Human Cationic Antimicrobial Protein (hCAP-18) Is Expressed in the Epithelium of Human Epididymis, Is Present in Seminal Plasma at High Concentrations, and Is Attached to Spermatozoa. <i>Infection and Immunity</i> , 2000, 68, 4297-4302.	2.2	200
301	Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections. <i>Urology</i> , 2000, 56, 682-688.	1.0	21
302	Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. <i>Urology</i> , 2000, 55, 694-699.	1.0	76
303	HUMAN GLANDULAR KALLIKREIN 2: A POTENTIAL SERUM MARKER FOR PREDICTING THE ORGAN CONFINED VERSUS NONORGAN CONFINED GROWTH OF PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 163, 1491-1497.	0.4	80
304	DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM. <i>Journal of Urology</i> , 2000, 163, 311-316.	0.4	78
305	DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM. <i>Journal of Urology</i> , 2000, , 311.	0.4	1
306	Quantitative Reverse Transcription-PCR Assay with an Internal Standard for the Detection of Prostate-specific Antigen mRNA. <i>Clinical Chemistry</i> , 1999, 45, 1397-1407.	3.2	38

#	ARTICLE	IF	CITATIONS
307	Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. FEBS Journal, 1999, 266, 1050-1055.	0.2	36
308	Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer and Prostatic Diseases, 1999, 2, 91-97.	3.9	34
309	Time-resolved fluorescence imaging (TRFI) for direct immunofluorescence of PSA and alpha-1-antichymotrypsin in prostatic tissue sections. Prostate Cancer and Prostatic Diseases, 1999, 2, 140-147.	3.9	7
310	Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections. The Histochemical Journal, 1999, 31, 45-52.	0.6	21
311	The Proportion of Carboxylated to Total or Intact Osteocalcin in Serum Discriminates Warfarin-Treated Patients from Control Subjects. Journal of Bone and Mineral Research, 1999, 14, 555-560.	2.8	23
312	Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn <sup>2+</sup> and extracellular protease inhibitors. FEBS Journal, 1999, 262, 781-789.	0.2	86
313	Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. Urology, 1999, 53, 945-950.	1.0	44
314	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. Urology, 1999, 54, 753-762.	1.0	1
315	SIGNIFICANCE AND METABOLISM OF COMPLEXED AND NONCOMPLEXED PROSTATE SPECIFIC ANTIGEN FORMS, AND HUMAN GLANDULAR KALLIKREIN 2 IN CLINICALLY LOCALIZED PROSTATE CANCER BEFORE AND AFTER RADICAL PROSTATECTOMY. Journal of Urology, 1999, 162, 2029-2035.	0.4	47
316	HK2 MEASUREMENTS IN A RANDOMLY SELECTED, POPULATION BASED SCREENING FOR PROSTATE CANCER. Journal of Urology, 1999, , 320.	0.4	3
317	Semenogelin I and semenogelin II, the major gel-forming proteins in human semen, are substrates for transglutaminase. FEBS Journal, 1998, 252, 216-221.	0.2	63
318	Cloning and characterization of the $\alpha$ 1-antichymotrypsin produced by human prostate tissue. , 1998, 34, 155-161.		5
319	Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Science, 1998, 7, 259-269.	7.6	60
320	Rapid Exponential Elimination of Free Prostate-Specific Antigen Contrasts the Slow, Capacity-Limited Elimination of PSA Complexed to Alpha1-Antichymotrypsin From Serum. Urology, 1998, 51, 57-62.	1.0	76
321	Cloning and characterization of the $\alpha$ 1-antichymotrypsin produced by human prostate tissue. Prostate, 1998, 34, 155-161.	2.3	1
322	MOLECULAR FORMS OF SERUM PROSTATE-SPECIFIC ANTIGEN. Urologic Clinics of North America, 1997, 24, 353-365.	1.8	50
323	Activation of the Zymogen Form of Prostate-Specific Antigen by Human Glandular Kallikrein 2. Biochemical and Biophysical Research Communications, 1997, 238, 549-555.	2.1	195
324	Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Clinica Chimica Acta, 1997, 257, 117-132.	1.1	37

#	ARTICLE	IF	CITATIONS
325	Chemical Characterization of the Predominant Proteins Secreted by Mouse Seminal Vesicles. FEBS Journal, 1997, 249, 39-44.	0.2	33
326	Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. , 1997, 31, 84-90.		21
327	The Significance of Serpins in the Regulation of Proteases in the Male Genital Tract. Advances in Experimental Medicine and Biology, 1997, 425, 163-176.	1.6	2
328	A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Journal of Urology, 1996, 156, 350-354.	0.4	99
329	Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology, 1996, 48, 240-248.	1.0	52
330	Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology, 1996, 48, 317-325.	1.0	122
331	Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology, 1996, 48, 882-888.	1.0	65
332	In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to $\alpha$ -1-antichymotrypsin in blood samples. Urology, 1996, 48, 81-87.	1.0	117
333	Isolation and Characterization of the Major Gel Proteins in Human Semen, Semenogen I and Semenogen II. FEBS Journal, 1996, 238, 48-53.	0.2	58
334	Structural investigation of the alpha-1-antichymotrypsin: Prostate-specific antigen complex by comparative model building. Protein Science, 1996, 5, 836-851.	7.6	32
335	Succesful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. Cancer Treatment and Research, 1996, 88, 93-101.	0.5	7
336	A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates. Journal of Urology, 1996, 156, 350-354.	0.4	22
337	Biologic Function of Prostate-Specific Antigen: Enzyme Action and Reactions with Extracellular Protease Inhibitors. European Urology, 1995, 27, 2-3.	1.9	1
338	Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology, 1995, 45, 447-453.	1.0	27
339	Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology, 1995, 45, 729-744.	1.0	283
340	Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and Ratios. Journal of Urology, 1995, 154, 1090-1095.	0.4	305
341	Seminal Progastricsin. Advances in Experimental Medicine and Biology, 1995, 362, 101-105.	1.6	2
342	Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. FEBS Journal, 1994, 220, 45-53.	0.2	166

#	ARTICLE	IF	CITATIONS
343	Alpha1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. <i>Urology</i> , 1994, 43, 427-434.	1.0	133
344	Comparability of the tandem-R and IMx assays for the measurement of serum prostate-specific antigen. <i>Urology</i> , 1994, 44, 512-518.	1.0	34
345	Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. <i>Urology</i> , 1993, 42, 502-510.	1.0	86
346	Serum Prostate Specific Antigen Complexed to $\alpha$ 1-Antichymotrypsin as an Indicator of Prostate Cancer. <i>Journal of Urology</i> , 1993, 150, 100-105.	0.4	629
347	SIGNIFICANCE OF DIFFERENT MOLECULAR FORMS OF SERUM PSA. <i>Urologic Clinics of North America</i> , 1993, 20, 681-686.	1.8	80
348	Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 4559-4563.	7.1	88
349	Prostate specific antigen predominantly forms a complex with alpha1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. <i>Cancer</i> , 1992, 70, 230-234.	4.1	100
350	Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system.. <i>Journal of Clinical Investigation</i> , 1992, 89, 1094-1101.	8.2	143
351	Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. <i>FEBS Journal</i> , 1990, 194, 755-763.	0.2	578
352	The microheterogeneity of desialylated $\alpha$ 1-antichymotrypsin: the occurrence of two amino-terminal isoforms, one lacking a His-Pro dipeptide. <i>BBA - Proteins and Proteomics</i> , 1989, 997, 90-95.	2.1	30
353	Molecular cloning of a small prostate protein, known as $\alpha$ 2-microsemenoprotein, PSP94 or $\alpha$ 2-inhibin, and demonstration of transcripts in non-genital tissues. <i>Biochemical and Biophysical Research Communications</i> , 1989, 164, 1310-1315.	2.1	63
354	Three predominant proteins secreted by the human prostate gland. <i>Prostate</i> , 1988, 12, 29-38.	2.3	179
355	Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. <i>Prostate</i> , 1988, 12, 39-46.	2.3	138
356	Molecular cloning of human prostate specific antigen cDNA. <i>FEBS Letters</i> , 1987, 214, 317-322.	2.8	340
357	Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen.. <i>Journal of Clinical Investigation</i> , 1987, 80, 281-285.	8.2	319
358	Familial $\alpha$ 1-Antichymotrypsin Deficiency. <i>Acta Medica Scandinavica</i> , 1986, 220, 447-453.	0.0	42
359	Isolation and characterization of two minor fractions of $\alpha$ 1-antitrypsin by high-performance liquid chromatographic chromatofocusing. <i>Journal of Chromatography A</i> , 1985, 327, 173-177.	3.7	43
360	The predominant protein in human seminal coagulate. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1985, 45, 635-641.	1.2	88

#	ARTICLE	IF	CITATIONS
361	A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.. Journal of Clinical Investigation, 1985, 76, 1899-1903.	8.2	638
362	Liquefaction of coagulated human semen. Scandinavian Journal of Clinical and Laboratory Investigation, 1984, 44, 447-452.	1.2	108